Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) CEO Brian Lian sold 1,000 shares of the stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $69.90, for a total transaction of $69,900.00. Following the sale, the chief executive officer now owns 2,354,927 shares of the company’s stock, valued at approximately $164,609,397.30. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Brian Lian also recently made the following trade(s):
- On Monday, August 19th, Brian Lian sold 112,870 shares of Viking Therapeutics stock. The stock was sold at an average price of $65.80, for a total transaction of $7,426,846.00.
- On Tuesday, July 30th, Brian Lian sold 115,859 shares of Viking Therapeutics stock. The shares were sold at an average price of $57.58, for a total transaction of $6,671,161.22.
Viking Therapeutics Price Performance
Shares of NASDAQ:VKTX opened at $64.63 on Friday. The company has a 50 day moving average of $55.23 and a 200-day moving average of $61.45. Viking Therapeutics, Inc. has a one year low of $8.28 and a one year high of $99.41. The stock has a market cap of $7.16 billion, a price-to-earnings ratio of -69.49 and a beta of 1.03.
Viking Therapeutics (NASDAQ:VKTX – Get Free Report) last released its earnings results on Wednesday, July 24th. The biotechnology company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.06. During the same quarter last year, the business posted ($0.19) EPS. Equities research analysts anticipate that Viking Therapeutics, Inc. will post -0.99 earnings per share for the current year.
Institutional Investors Weigh In On Viking Therapeutics
A number of institutional investors have recently made changes to their positions in VKTX. Aristides Capital LLC lifted its stake in Viking Therapeutics by 120.0% in the second quarter. Aristides Capital LLC now owns 11,000 shares of the biotechnology company’s stock valued at $583,000 after buying an additional 6,000 shares during the period. Cetera Investment Advisers grew its position in shares of Viking Therapeutics by 114.0% during the 2nd quarter. Cetera Investment Advisers now owns 49,311 shares of the biotechnology company’s stock worth $2,614,000 after buying an additional 26,270 shares during the period. Truist Financial Corp increased its stake in shares of Viking Therapeutics by 357.1% in the 2nd quarter. Truist Financial Corp now owns 26,049 shares of the biotechnology company’s stock valued at $1,381,000 after acquiring an additional 20,350 shares during the last quarter. Second Line Capital LLC acquired a new stake in shares of Viking Therapeutics in the 2nd quarter valued at approximately $1,506,000. Finally, Creative Planning raised its position in shares of Viking Therapeutics by 3.4% in the 2nd quarter. Creative Planning now owns 15,753 shares of the biotechnology company’s stock valued at $835,000 after acquiring an additional 524 shares during the period. 76.03% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
VKTX has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $90.00 price target on shares of Viking Therapeutics in a report on Thursday, July 25th. Truist Financial reiterated a “buy” rating and set a $120.00 price target on shares of Viking Therapeutics in a research report on Monday, June 17th. StockNews.com raised shares of Viking Therapeutics to a “sell” rating in a report on Wednesday, July 31st. Raymond James raised their price objective on shares of Viking Therapeutics from $116.00 to $118.00 and gave the company a “strong-buy” rating in a research report on Thursday, July 25th. Finally, Maxim Group reissued a “buy” rating and set a $120.00 price target on shares of Viking Therapeutics in a research note on Tuesday, June 4th. One investment analyst has rated the stock with a sell rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $111.78.
View Our Latest Stock Report on VKTX
About Viking Therapeutics
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
See Also
Receive News & Ratings for Viking Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Viking Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.